JPRN-UMIN000023254未知1 期
PhaseI/II prospective multi-center clinical trial of intra-arterial infusion of imipenem/cilastatin sodium particle for type1 complex regional pain syndrome in forward arm and hand - PhaseI/II study of intra-arterial infusion for CRPS1 in forward arm and hand
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •passed more than 12months from onset severe arteriosclerosis HbA1C>8.5 the history of allergy to contrast enhance
研究者
相似试验
尚未招募
不适用
Phase I / II, Multicenter Clinical trial to evaluate the safe dose range and confirm the effectiveness and safety of the maximum tolerated dose of Docetaxel In combination with SH003 in patients with solid tumor who are indicated for DocetaxelKCT0004770Korea University Anam Hospital110
进行中（未招募）
不适用
Phase II prospective randomized multicenter study of Folfiri versus Folfiri Cox-2 inhibitor versus Folfiri followed by Cox-2 inhibitor in the first-line treatment of colo-rectal cancerEUCTR2004-000591-13-ITISTITUTO ONCOLOGICO ROMAGNOLO159
进行中（未招募）
2 期
A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed aggressive LymphomaC83.3Diffuse large B-cell lymphomaDRKS00023793niversitätsmedizin der Johannes Gutenberg-Universität Mainz26
进行中（未招募）
1 期
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma.Malignant B-cell lymphomaMedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002373-59-DEniversity Medical Center of the Johannes Gutenberg University Mainz64
已完成
不适用
Virtual Care of Acute DiverticulitisAcute diverticulitisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Studies of infection and infectious agentsACTRN12621000692831Surgical Outcomes Research Centre, Royal Prince Alfred Hospital50